Special Issue

Antiviral Antibody Immune Responses in the Context of Vaccination and Infection

Message from the Guest Editors

Antiviral antibody responses are crucial for defending against viral infections, especially in the context of emerging diseases. Neutralizing antibodies, which prevent viral entry into host cells, are a key vaccine goal due to their long-lasting protection. However, rapid viral mutations, as seen with influenza and SARS-CoV-2, can reduce vaccine efficacy. New-generation vaccines have transformed antiviral immunity by eliciting strong antibody responses and adapting quickly to viral variants. Novel adjuvants enhance antibody quality and durability by modulating immune activation and promoting broadly neutralizing antibodies. We welcome studies on antibody generation, neutralizing antibody roles, vaccine-induced vs. natural immunity, antibody properties, and B cell responses. Research on newgeneration vaccines and novel adjuvants is highly encouraged. Additionally, we invite research on novel adjuvants and their role in enhancing the quality, durability, and breadth of antiviral antibody responses.

Guest Editors

Prof. Dr. Jagadeesh Bayry

- 1. INSERM, Centre de Recherche des Cordeliers, Sorbonne Université, F-75006 Paris, France
- 2. Indian Institute of Technology Palakkad, Kerala 678623, India

Dr. Guglielmo Lucchese

Department of Experimental Medicine, University of Salento, Via Lecce-Monteroni, 73047 Lecce, Italy

Deadline for manuscript submissions

15 December 2025



an Open Access Journal by MDPI

Impact Factor 2.7 CiteScore 4.5 Indexed in PubMed



mdpi.com/si/239122

Antibodies
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibodies@mdpi.com

mdpi.com/journal/ antibodies





an Open Access Journal by MDPI

Impact Factor 2.7 CiteScore 4.5 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Editor-in-Chief

Prof. Dr. Arne Skerra

Institute of Biological Chemistry, Technical University Munich, Emil-Erlenmeyer-Forum 5, 85350 Freising-Weihenstephan, Germany

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

CiteScore - Q2 (Drug Discovery)

